Respi4Doctors est une plate-forme numérique via laquelle AstraZeneca offre des informations et des services en rapport avec le traitement des troubles respiratoires.
Post-hoc analyse START
For the past 25 years, most asthma guidelines have consistently recommended treatment according to level of baseline symptom frequency. Patients with intermittent symptoms (2 days or fewer per week) are generally prescribed a SABA, while only patients with so-called persistent asthma are eligible for ICS therapy.
The findings from the recent post-hoc analysis of the START study, published in the Lancet, challenge long-standing assumptions about the risks of so-called mild asthma. The study suggests that decisions about ICS treatment in such patients should be made on the basis of population risk reduction, rather than only on symptom frequency.
This slide kit provides more details on this recent publication from the Lancet.